Hilda Frederique Scharen-Guivel
CIK: 0001950129
Associated companies
Transaction History
| IRMD | ▼ Sell | Open Market | 1,766 | $168K | 6/4/2026 | View on chart |
| IRMD | ▼ Sell | Open Market | 1,234 | $117K | 6/4/2026 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 905 | — | 12/11/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,197 | — | 12/7/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,767 | — | 10/14/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,196 | — | 12/7/2024 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,767 | — | 10/14/2024 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,766 | — | 10/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
iRadimed Gets Needham Hold Rating and Conference Participation
Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.
iRadimed Gets Needham Hold Rating and Conference Participation. Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.